Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 10 Polycystic Ovary Syndrome 4 Prostatic Neoplasms 2 Heart Failure 2 Cardiotoxicity 2 Solid Tumors 1 Pediatric Brain Tumor 1 Pancreatic Neoplasms 1 Obesity 1 Lung Neoplasms 1 Inflammation 1 Hyperinsulinism 1 Adenocarcinoma of Lung 1

Interventions

Sunitinib 4 Cyclophosphamide 4 Capecitabine 4 Bevacizumab 4 pazopanib 3 Topotecan 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 temsirolimus 2 liposomal doxorubicin 2 fludarabine 2 Sorafenib 2 Panobinostat 2 NVP-BKM120 2 Lapatinib 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Bortezomib 2 vadimezan 1 spartalizumab 1 somatostatin receptor 2 1 selinexor 1 selicrelumab 1 perifosine 1 pegylated granulocyte colony-stimulating factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumors × dapagliflozin × Clear all

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡